NSCLC and breast cancer were enriched for KD mutations (69.9% and 77.0% of ERBB2 mutations, respectively), whereas bladder cancer was dominated by ECD mutations (63.6%). Here, ERBB2 is linked to non-small cell lung carcinoma.